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Abstract 
Defects in motor protein-mediated neuronal transport mechanisms have been implicated in a number of 
neurodegenerative disorders but remain relatively little studied in Alzheimer’s disease (AD). Our aim in the 
present study was to assess the expression of the anterograde kinesin superfamily motor proteins KIF5A, KIF1B 
and KIF21B, and to examine their relationship to levels of hyperphosphorylated tau, amyloid-β protein precursor 
(AβPP) and amyloid-β (Aβ) in human brain tissue. We used a combination of qPCR, immunoblotting and ELISA 
to perform these analyses in midfrontal cortex from 49 AD and 46 control brains. Expression of KIF5A, KIF1B 
and KIF21B at gene and protein level was significantly increased in AD. KIF5A protein expression correlated 
inversely with the levels of AβPP and soluble Aβ in AD brains. Upregulation of KIFs may be an adaptive response 
to impaired axonal transport in AD. 
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Introduction 
Neuronal health in the central nervous system is dependent on a range of physiological processes which maintain 
cellular structure, ion homeostasis, electrical activity and synaptic function. The transport of cellular organelles 
and proteins throughout the neuron, including along the axon and dendrites, is crucial for maintenance of neuronal 
structure and function. Defects in motor protein-mediated neuronal transport mechanisms have been implicated 
in a number of neurodegenerative disorders [1]. 
Transport within neurons is mediated by multiple motor proteins, many of which are involved in synaptic 
transmission and axonal trafficking.  Kinesin superfamily proteins (KIFs) comprise a large group of motor proteins 
whose primary role is the anterograde axonal transport and intraneuronal transport of protein cargoes through 
association with microtubule ‘rails’ [2].   Currently, there are 45 known members of the KIF family, 38 of which 
are neuronally enriched [3]. The majority of KIFs have an NH2-terminal head, comprising a microtubule binding 
domain and a conserved globular motor domain which hydrolyses ATP to produce the energy required for 
movement of cargoes along the microtubule and through the axon. The head is attached by an α-helical stalk to a 
COOH-terminal (tail) to which cargoes bind [2, 4].  In most cases, the tail domain of each KIF determines its 
cargo specificity. In terms of conventional kinesin, cargoes can bind directly or indirectly, through kinesin light 
chain (KLC) associations and protein adaptor complexes, to the tail domain [5]. Essential neuronal cargoes 
transported by KIFs include cellular organelles such as mitochondria, pre- and post- synaptic membrane proteins, 
and a range of structural proteins such as neurofilaments (NFs) [1].   
Given the essential role of KIFs in protein trafficking, it is not surprising that mutations in KIFs are associated 
with neurodegenerative diseases. Point mutations in the KIF5A gene have been linked to several axonopathies 
including hereditary spastic paraplegia type 10 (SPG-10) [6] and Charcot-Marie Tooth disease type 2A (CMT-
2A) [7]. SPG10 is implicated in disturbed intracellular axonal transport and is characterized by axonal loss in the 
corticospinal tract [6, 8]. Animal gene knock-out studies have also highlighted the importance of KIF5A in axonal 
transport and neuronal development [9]. In addition, single nucleotide polymorphisms (SNPs) within the KIF5A 
gene locus (rs12368653 and rs703842) have also been linked to multiple sclerosis (MS) susceptibility [10, 11], 
and we previously found levels of KIF5A protein in MS tissue to be related to SNP copy number [12, 13]. KIF5A 
is believed to transport amyloid β precursor protein (AβPP), mitochondria and a range of pre-synaptic membrane 
proteins that form the SNARE complex [9, 14-18]. The majority of these cargoes bind indirectly to KIF5A through 
KLCs.  
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SNPs in the region of the KLC1 gene have been associated with Alzheimer’s disease (AD) susceptibility [19].  
Andersson et al [20] reported that SNPs in KLC1 were associated with APOE ε4 carrier status and with the 
cerebrospinal fluid level of hyperphosphorylated tau in mild cognitive impairment patients who converted to AD 
during follow-up; suggesting that variability in axonal transport could influence early AD pathogenesis. In support 
of this theory, studies using familial AD (FAD) AβPP over-expressing transgenic mice have shown abnormal 
axonal morphology and large axonal swellings co-positive for KLC and phosphorylated NF-H within 4 months 
of birth [21]. In addition, transgenic mice with modified presenilin-1 expression have demonstrated reduced 
affinity between KLC and membrane bound organelles (such as synaptophysin and syntaxin-I containing 
vesicles), mediated via KLC phosphorylation by elevated glycogen synthase kinase 3β (GSK-3β) activity. 
Elevated GSK-3β activity has also been directly associated with levels of hyperphosphorylated tau in FAD models 
[22, 23]. The formation of intraneuronal neurofibrillary tangles (NFTs), composed of aggregated 
hyperphosphorylated tau protein, is a cardinal feature of AD. Under physiological conditions tau interacts with 
tubulin as a microtubule stabiliser [24], forming an important contributor to the structure and integrity of the axon 
for signal conductance. We have previously found reduced KIF5A, KIF1B and KIF21B expression in multiple 
sclerosis tissue [12] and demonstrated significant inverse correlations between KIF5A and cargo expression, 
suggesting that lower levels of KIF5A contribute to the axonal aggregation of proteins that lead to the formation 
of axonal spheroids, commonly seen in the disease [13]. KIF1B and KIF21B were studied as they have been 
linked to MS susceptibility [25, 26]. KIF1B is believed to share functional redundancy with KIF5A for neuronal 
protein cargoes and a mutation in its motor domain is also linked to CMT-2A [27]. KIF21B is dendritically 
enriched and involved in post-synaptic protein transport [28]. 
As intraneuronal aggregation of proteins is also a feature of AD, a disease in which neuronal protein transport is 
likely impaired [29], we thought it would be of interest to assess KIF5A, KIF1B and KIF21B expression in AD 
and to analyse the relationship between these KIF motors and the levels of AβPP, Aβ and hyperphosphorylated 
tau. 
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Materials and methods 
Study Cohort 
Samples of midfrontal cortex (BA 9) cDNA and protein homogenate were obtained from the South West Dementia 
Brain Bank (Bristol, UK), under the terms of South West - Central Bristol Research Ethics Committee approval 
no 08/H0106/28+5. We studied 49 cases of AD (in which, according to the National Institute on Aging – 
Alzheimer's Association criteria [30], AD neuropathological change was an adequate explanation of dementia) 
and 46 age-matched controls without a history of cognitive impairment (Table 1). 
 
Quantitative real-time PCR (qPCR) 
Quantitative real-time qPCR was performed on a StepOnePlus™ Real-Time PCR system with StepOne software 
v2.1 (Applied Biosystems; Fisher Scientific UK Ltd, Loughborough, UK). Control and AD cDNA samples were 
used at a concentration of 2 ng/µL, diluted to a final volume of 20 µL with TaqMan® 2x Fast Advanced Master 
Mix and TaqMan® gene expression assays for KIF5A (Hs01007893_m1), KIF1B (Hs01114538_m1) and KIF21B 
(Hs01118428_m1; FAM-MGB dye-labelled) (Applied Biosystems). qPCR was performed on a FAST ramp speed 
holding at 50°C for 2 min, 95°C for 20 s, followed by 40 cycles at 95°C for 1 s and 60°C for 20 s. Gene expression 
(2-ΔΔct) was calculated relative to the gene encoding the neuron-specific protein NeuN (RBFOX3; 
Hs01370653_m1; FAM-MGB dye-labelled) and neuron-specific enolase 2 (ENO-2; Hs00157360_m1; FAM-
MGB dye-labelled) (Applied Biosystems). 
 
Western blotting 
All primary antibodies that we used in dot blots were initially tested for antibody specificity by western blot. 
Protein homogenates were diluted 1:1 with Laemmli 2x sample buffer (Sigma-Aldrich Ltd; Dorset, UK) and 
heated to 95°C for 5 min to denature the protein before applying to gels.  A Mini-PROTEAN Tetra Cell was 
constructed with mini-Protean TGX gels (4-20%) (Biorad Hertfordshire, UK).  The Tetra Cell chambers were 
filled with Tris/Glycine/SDS running buffer (Biorad), before we loaded 7 μL BLUeye Prestained Protein Ladder 
(Geneflow; Staffordshire, UK) and 15 μL of denatured AD protein homogenate in the remaining lanes. The gel 
was run for approximately 1 h (until the dye front reached the gel bottom) at 150 V.  Proteins on the gel were then 
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transferred onto nitrocellulose membrane for 90 min at 350 mA.  Nitrocellulose membrane from the gel transfer 
was blocked in 5% BSA/Tris-buffered saline-Tween 20 (TBS-T) or 5% milk/TBS-T (depending on antibody), for 
1 h at room temperature before its incubation with primary antibody (reconstituted in membrane blocking 
solution), overnight at 4°C.  Primary antibodies used for blotting were as follows: rabbit anti-KIF5A (Sigma-
Aldrich Ltd; HPA004469), mouse anti-GAPDH (Abcam; Ab9484); mouse anti-AβPP (Zymed; Life Technologies 
Ltd; Paisley, UK; 13-0200), rabbit anti-KIF21B (Sigma-Aldrich Ltd; HPA027274), rabbit anti-NEUN (Abcam; 
Ab177487), mouse anti-PHF-TAU (Invitrogen; Fisher Scientifc UK Ltd; MN1020) and rabbit anti-KIF1B (Bethyl 
Laboratories; Montgomery, USA; A301-055A). Optimal antibody concentration and the specific blocking 
solution used are detailed in Table 2. Bound primary antibody was detected by incubation with HRP-conjugated 
goat anti-rabbit IgG pre-adsorbed (1:10,000; Ab6721) or goat anti-mouse IgG (1:5000; Ab6789) secondary 
antibodies (both Abcam), for 1 h at room temperature.  Protein expression was visualised using a 
chemiluminescence EZ-ECL kit (1:1; Geneflow), in conjunction with a Biorad Universal III Bioplex imager.  
Densitometric band analysis was performed using Image Lab™ 5.0 software (Biorad).  All antibodies displayed 
specific bands as described on manufacturer data sheets and consistent with their reported molecular weights 
(Supplementary Figure 1). 
 
Dot blotting 
Dot blotting was performed with antibodies we had validated for specificity by western blot, as listed in Table 2. 
Nitrocellulose membrane was pre-soaked in 1x TBS, before placement in the 96-well Bio-Dot Microfiltration 
manifold (Biorad). The manifold was assembled according to the manufacturer’s protocol. Frontal lobe protein 
homogenates were diluted (1:75) with 1x TBS, and 100 µL of each sample (49 AD and 46 control) was transferred 
by microfiltration for 90 min, including a blank TBS control well. In order to maximise the sample size available 
on the 96-well manifold, technical replicates were not used. The nitrocellulose membrane was subsequently 
removed from the manifold for blocking, antibody incubation and chemiluminescence visualisation, as per the 
western blotting protocol. Densitometric analysis of protein dots was performed using Image Lab™ 5.0 software 
(Biorad).  Integrated density values were expressed relative to the neuronal control protein NeuN.  
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Tissue preparation for soluble and insoluble (guanidine-extractable) Aβ measurements 
Approximately 200 mg of frontal tissue was homogenised in TBS extraction buffer as previously described [31]. 
In brief, homogenates were centrifuged at 20, 817g for 15 min at 4°C and the supernatant (soluble fraction) stored 
at −80°C until use. The remaining pellet was homogenised in 6.25 M guanidine HCl (50 mM Tris/HCl (pH 8.0)) 
and incubated for 4 h at 25°C, followed by centrifugation at 20, 817g for 20 min, at 4°C. The supernatant 
(guanidine-extractable fraction) was stored at −80°C until use. 
 
Enzyme-linked immunosorbent assay (ELISA) 
Sandwich ELISA was used to measure total Aβ in the soluble and insoluble (guanidine-HCl-extractable) fractions 
of the homogenates, as previously described [32]. Monoclonal anti-Aβ (4G8 clone, raised against amino acids 18-
22; Millipore; Watford, UK), was used for the capture step and biotinylated anti-human Aβ monoclonal antibody 
(10H3 clone) (Thermo Fisher Scientific; Northumberland, UK), for the detection step. 
 
Statistical analysis 
Univariate mRNA and protein analysis was carried out using GraphPad Prism5™ (GraphPad Software Inc.; San 
Diego, USA).  Data normality was tested using the Shapiro-Wilk test. Unpaired t-tests or non-parametric Mann-
Whitney tests, as appropriate, were used to compare mRNA and protein data between the AD and control cohorts. 
Parametric Pearson’s or non-parametric Spearman’s correlation was used to interpret any relationship between 
proteins. One-way ANOVA with post-hoc Bonferroni was used to analyse KIF data categorised by Braak score. 
A multiple regression model (STATA v12; StataCorp LLC; Texas, USA) was used to analyse mRNA and protein 
expression in relation to disease, patient age of death, tissue post-mortem delay and gender. Where necessary, 
data was transformed to normality before performing regression analysis. For all tests, values of p < 0.05 were 
considered statistically significant. 
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Results 
Cohort variances 
The 49 AD cases used ranged from 54-98 y (mean = 81 y, SD = 9 y) and the 46 control cases used from 43-95y 
(mean = 79 y, SD = 11 y). In keeping with AD incidence, there was a higher proportion of female cases in the AD 
group (61.2%) compared with male (38.8%) and roughly an even gender split in control cases (female: 45.7%; 
male 54.3%). There was no significant difference in tissue post-mortem delay between AD (mean = 40 h, SD = 
21 h) and control samples (mean = 43 h, SD = 38 h) (two-tailed Mann-Whitney; p=0.63; Table 1). Multiple 
regression analysis revealed a significant effect of post-mortem delay (PMD) on mRNA expression (Table 3). 
Specifically, NeuN mRNA expression correlated inversely with tissue post-mortem delay (n=47, Spearman r = -
0.48, p=0.00). Subsequent analysis excluded cases with PMD >72 h. After exclusion, PMD still influenced NeuN 
mRNA expression (n=43, Spearman r = -0.45, p=0.00) but there was no effect of PMD on NeuN protein 
expression (n=76, Spearman r = -0.11, p=0.23). Therefore, KIF mRNA expression was normalised to an 
alternative neuronal house-keeping gene, neuron-specific enolase (ENO-2). There was no effect of PMD on ENO-
2 mRNA expression (n=42, Spearman r = 0.26, p=0.09). 
 
Upregulation of KIF genes in AD 
There was a 4-fold increase in KIF5A mRNA relative to ENO-2 mRNA in AD compared to controls (p < 0.001; 
Figure 1A). There was also a 3-fold increase in KIF1B mRNA in AD cases (p < 0.01; Figure 1B). There was no 
significant difference in KIF21B mRNA expression between control and AD cases (p = 0.32; Figure 1C). Multi-
regression analysis showed no effect of patient age of death, tissue post-mortem delay or gender on KIF mRNA 
expression, when normalised to ENO-2 (Table 3). 
 
Elevated KIF5A, KIF1B and KIF21B protein in AD 
Immuno dot-blot revealed significantly increased KIF5A protein in AD compared to control tissue, after 
adjustment for NeuN content (p < 0.05; Figure 2A). There were also significant increases in KIF1B (p < 0.001; 
Figure 2B) and KIF21B protein (p < 0.001; Figure 2C), after adjustment for NeuN. Multi-variate analysis showed 
no significant effect of tissue post-mortem delay or gender on KIF protein expression but there was a significant 
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effect of aging on KIF1B protein expression (Table 4). In order to establish whether increased KIF expression is 
an early event in AD pathogenesis, KIF expression was also sub-categorised according to Braak score, ranging 
from 0-6. One-way ANOVA with post-hoc Bonferroni did not reveal significant differences between the groups 
(Supplementary Table 1). 
 
KIF5A protein correlates inversely with hyperphosphorylated tau in AD brains 
As expected, we found a significant increase in hyperphosphorylated tau in AD compared to controls, adjusted 
for NeuN (p < 0.001; Figure 3). This was replicated in multi-variate analysis, however, there was a significant 
influence of patient age on tau expression (p<0.05, Table 4). Univariate analysis showed no correlation between 
KIF5A expression (adjusted for GAPDH [33]) and hyperphosphorylated tau (adjusted for NeuN) in control 
(Pearson r = -0.30, p=0.09) or AD cases (Spearman r -0.27, p=0.10; Table 5). Due to the influence of age, 
additional multi-variate analysis was performed which revealed a significant effect of KIF5A protein on 
hyperphosphorylated tau expression in AD cases (p=0.04, Table 6). Both univariate and multi-variate analysis 
showed no significant correlations between tau and KIF1B or KIF21B (Table 5 and Table 6). 
 
KIF5A protein correlates inversely with AβPP and soluble Aβ in AD 
AβPP protein level (adjusted for NeuN) was significantly elevated in AD tissue compared with control in 
univariate analysis (p<0.05; Figure 4A). However, this increase was not significant in subsequent multi-variate 
analysis, considering patient age of death, tissue PMD and gender (p=0.15, Table 4). There was a significant 
inverse correlation between KIF5A (adjusted for GAPDH) and AβPP protein level (adjusted for NeuN) in AD 
cases (Spearman r = -0.53, p < 0.001; Figure 4B) and control cases (Spearman r = -0.42, p<0.05; Table 5). As 
expected, there was a significant increase in insoluble Aβ levels in AD cases compared with control (two-tailed 
Mann-Whitney, p < 0.001), which was consolidated in multi-variate analysis (Table 4). There was no correlation 
between KIF5A expression and insoluble Aβ in AD cases (Pearson r = 0.05, p = -0.08; Table 5). Soluble Aβ was 
elevated in AD cases but not to significance (p = 0.06; Figure 4C), as verified in multi-variate analysis (p=0.05; 
Table 4). Like AβPP, soluble Aβ levels correlated inversely with KIF5A in AD cases (Pearson r = -0.49, p < 0.05; 
Figure 4D). Previous studies have suggested that the level of soluble Aβ tends to fall with increased deposition of 
insoluble Aβ [34, 35]. However, KIF5A level did not correlate with the ratio of soluble: insoluble Aβ in AD cases 
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(Spearman r = -0.35, p =0.09; Table 5). Univariate analysis showed no association between KIF21B or KIF1B 
with AβPP, soluble Aβ, insoluble Aβ and soluble:insoluble Aβ in control or AD cases (Table 5). Considering the 
effect of age on KIF1B expression, multi-variate analysis was also performed which showed no significant 
correlation between KIF1B and AβPP, soluble Aβ and insoluble Aβ, which was not affected by age 
(Supplementary Table 2). 
 
Discussion 
Dysregulated KIF expression has been investigated in relation to several neurodegenerative diseases but remains 
relatively little studied in AD [29, 36]. We have found increased KIF gene and protein expression in AD, and 
significant inverse correlations between KIF5A expression and AβPP and soluble Aβ in AD.  
KIF5A exists predominantly as a tetramer comprising two dimerised kinesin heavy chains, and two kinesin light 
chains (KLC1 and KLC2) attached at the tail domain of the KHCs. Studies in mice have shown KIF5A knock-
out is neonatal lethal and post-natal targeting of the gene results in reduced axon calibre, eventual axon loss and 
hind-limb paralysis [9]. KIF5A is believed to transport several cargoes through association with KLCs, including 
AβPP, phosphorylated NFs and SNARE complex components; SNAP-25 and syntaxin-1b [17]. It has been 
suggested that genetic variability in the KLC1 gene may influence the development of AD [20]. In mice, deletion 
of the KLC1 subunit leads to early selective defects of axonal transport of several cargoes including AβPP, NF 
and tau aggregates, causing cytoskeletal disorganisation [37].  
We found increased KIF5A protein in AD to be associated with elevated levels of the corresponding transcript. It 
is possible that KIF5A is upregulated as an adaptive response in an attempt to clear or circumvent large protein 
aggregates within the neuron or to compensate for potential reduced activity of other motors. Elevated KIF5A 
mRNA has also been found in brain tissue from demented compared to non-demented patients with Parkinson’s 
disease [38]. Univariate analysis showed a significant increase in AβPP levels in AD compared with control. 
However, this effect was lost in multi-variate analysis of the cohort, in keeping with previous studies [39, 40]. 
KIF5A protein levels correlated inversely with that of AβPP, as previously reported in MS white matter [13]. 
AβPP is a type I transmembrane protein with suspected roles in cell adhesion, regulation of gene expression, and 
iron export [41]. AβPP transport by KIF5A is thought to be mediated by KLC association with AβPP-containing 
vesicles [18]. The subcellular distribution of AβPP plays a critical role in its metabolism, including the cleavage 
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by β- and γ- secretases that generates pathogenic Aβ peptides [35, 42-52]. Maintenance of neuronal transport of 
AβPP by upregulation of KIF5A may help to maintain normal metabolism of AβPP (and thereby neuronal 
viability) for longer than would otherwise be the case. In support of this, although soluble Aβ levels were higher 
in AD than control tissue, the levels correlated inversely with that of KIF5A. KIF5A level was not related to the 
ratio of soluble: insoluble Aβ, suggesting that KIF5A does not significantly influence the deposition of Aβ. 
However, we hypothesise that upregulation of KIF5A may temporarily ameliorate the damaging effects of 
abnormal intracellular protein aggregates through maintained intraneuronal transport.  
NFTs form through aggregation of hyperphosphorylated tau [53]. Multi-variate analysis of our cohort revealed 
levels of hyperphosphorylated tau declined with age. This is likely to be influenced by many confounding 
variables such as diet, genetics and lifestyle [54]. However, taking aging into account, we found KIF5A levels 
correlated inversely with hyperphosphorylated tau levels in AD cases. This again supports the hypothesis that 
KIF5A upregulation is crucial in maintaining intraneuronal transport. However, the effectiveness of KIF5A-
mediated transport in AD still needs to be determined. Studies have reported that pathogenic forms of tau inhibit 
axonal transport through activation of the protein phosphatase 1/glycogen synthase kinase 3 (PP1/GSK3) pathway 
[55], which is believed to cause dissociation of KIF5A from its cargo through phosphorylation of KLC [29].  
KIF1B mRNA and protein levels were higher in AD than control tissue. KIF1B has two splice variants, KIF1Bα 
and KIF1Bβ, which exist as KHC monomers. KIF1Bα transports mitochondria, synaptic scaffolding molecules 
(SCAM) and post-synaptic density (PSD) proteins PSD-95 and PSD-97. KIF1Bβ transports synaptic vesicle 
precursors including synaptotagmin, synaptophysin and SV2.  In humans, a missense mutation in the KIF1Bβ 
gene is linked to CMT-2A [27], characterised clinically by weakness and atrophy of distal muscles, depressed or 
absent tendon reflexes and mild sensory loss.  The kif1bβ mutation results in a glutamine to leucine substitution 
in the ATP-binding site of the kif1bβ motor domain, which causes a reduction in microtubule-ATPase activity 
and consequent reduction in the transport of cargoes.  Impaired delivery of synaptic vesicle precursors to axons 
and nerve terminals contributes to progressive dysfunction of peripheral neurons [56].  Because of their 
overlapping cargoes, a level of functional redundancy is thought to exist between KIF1B and KIF5A. Campbell 
et al  [15] studied functional redundancy of KIFs in zebrafish and found that kif1b overexpression cannot 
compensate for loss of kif5a-mediated mitochondrial transport but suggested a dual function in maintaining 
peripheral sensory neuronal function through the transport of non-mitochondrial cargoes. These non-
mitochondrial cargoes are most likely to be synaptic proteins.  Indeed, rodent studies have suggested alternative 
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roles for KIF5A and KIF1B in modulating mitochondrial motility, suggesting KIF1B overexpression reduces 
mitochondrial transport, whereas KIF5A overexpression increases motility [57]. We had considered the possibility 
that elevated KIF5A might partly be a physiological compensatory response to reduced KIF1B. We found both 
KIF5A and KIF1B to be elevated in AD, however, further investigation of family isoforms, in particular KIF1Bα 
and KIF1Bβ, could help elucidate potential subunit redundancy. The precise affinity of KIF5A for cargoes such 
as AβPP and the degree of functional redundancy between axonal motors from different sub-groups remains an 
open question [58].  
The anterograde motor protein KIF21B was increased in AD compared with control tissue. KIF21B is enriched 
in the dendrites and transports γ2-subunit-containing GABAA receptor vesicles. Altered expression of KIF21B 
may be involved in the regulation of receptor density that mediates GABAergic synaptic plasticity [28]. Kreft et 
al [59] found that KIF21B mRNA was increased in early-onset AD ( < 62 y at the time of death) and that the level 
correlated with shorter disease duration, and increased disease severity as assessed by neuropathology. In our 
study, the elevation in KIF21B mRNA in AD was not statistically significant. However, the mean age at death in 
our AD cohort was 81 y, and Kreft et al did not find any increase in KIF21B mRNA in an older AD cohort ( > 72 
y at death).  
In summary, we have found upregulation of three KIFs in AD. It remains to be determined whether upregulation 
is an adaptive response that helps to maintain intraneuronal transport and stabilise axonal structure in AD or 
whether it contributes to neurodegeneration. 
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Tables 
Table 1. Clinical characteristics of Alzheimer’s disease and control patient cohort. 
Patient 
ID 
Age (yrs) 
Sex 
(M/F) 
Post-mortem 
delay (hrs) 
Braak 
stage 
Patient 
ID 
Age (yrs) 
Sex 
(M/F) 
Post-mortem 
delay (hrs) 
Braak 
stage 
AD 1 89 F 71 5 C 1 62 M 4 0 
AD 2 78 F 77 6 C 2 95 F 46 0 
AD 3 78 F 9 5 C 3 78 F 24 2 
AD 4 81 F 42 6 C 4 83 M 80 3 
AD 5 91 F 37 4 C5 64 M 12 2 
AD 6 77 F 43 4 C 6 64 M 16 0 
AD 7 96 F 53 4 C 7 80 M 106 2 
AD 8 87 F 72 5 C 8 90 M 45 2 
AD 9 87 F 67 5 C 9 81 F 103 2 
AD 10 79 F 70 3 C 10 64 M 23 2 
AD 11 81 M 29 4 C 11 77 M 55 1 
AD 12 91 F 70 5 C 12 80 M 12 2 
AD 13 78 F 35 6 C 13 73 M 36 2 
AD 14 83 F 43 5 C 14 88 F 62 2 
AD 15 70 F 25 6 C 15 88 F 72 0 
AD 16 78 F 4 5 C 16 93 F 18 2 
AD 17 69 M 48 5 C 17 80 F 92 0 
AD 18 74 M 50 5 C 18 88 F 28 2 
AD 19 80 F 21 5 C 19 82 M 30 2 
AD 20 95 M 48 3 C 20 84 M 48 3 
AD 21 89 F 4 6 C 21 90 M 48 2 
AD 22 79 M 28 6 C 22 75 M 48 2 
AD 23 85 M 66 6 C 23 89 F 15 2 
AD 24 95 F 74 3 C 24 73 M 33 1 
AD 25 81 F 66 4 C 25 69 M 66 2 
AD 26 80 M 31 6 C 26 73 F 59 1 
AD 27 90 F 21 4 C 27 83 F 24 2 
AD 28 57 F 24 5 C 28 82 M 3 2 
AD 29 54 F 24 6 C 29 79 M 24 - 
AD 30 84 F 20 5 C 30 43 F 12 - 
AD 31 78 M 21 3 C 31 76 F 12 - 
AD 32 93 M 20 6 C 32 84 F 17 1 
18 
 
AD 33 80 M 5 6 C 33 82 F 37 2 
AD 34 87 F 55 5 C 34 72 F 24 0 
AD 35 74 M 24 5 C 35 78 M 48 1 
AD 36 89 F 39 5 C 36 81 M 3 2 
AD 37 84 M 64 5 C 37 82 M 56 2 
AD 38 73 F 38 5 C 38 76 M 23 2 
AD 39 68 M 61 6 C 39 91 F 60 2 
AD 40 83 M 48 5 C 40 82 F 96 3 
AD 41 74 M 48 5 C 41 77 M 10 3 
AD 42 78 M 49 6 C 42 75 M 6 3 
AD 43 78 M 50 6 C 43 48 F 79 4 
AD 44 85 M 50 6 C 44 93 F 53 3 
AD 45 98 F 21 5 C 45 84 F 216 2 
AD 46 83 F 32 6 C 46 90 M 6 2 
AD 47 69 M 12 5      
AD 48 87 F 28 6      
AD 49 84 F 21 6      
Mean 81 (+/- 9) - 40 (+/- 21) - Mean 79 (+/- 11) - 43 (+/- 38) - 
Cases highlighted in red (post-mortem delay >72hrs) were removed from statistical analysis. Abbreviations: AD: Alzheimer’s disease; C: control; F: female; Hrs: hours; M: 
male; Yrs: years. 
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Table 2. Antibodies used for immunoblotting. 
Antigen Species Blocking Antibody WB/DB Concentration Product Code Company 
AβPP Mouse 5% milk/TBS-Tween 1:2000 13-0200 Zymed 
GAPDH Mouse 5% BSA/TBS-Tween 1:10,000 Ab9484 Abcam 
PHF-TAU Mouse 5% BSA/TBS-Tween 1:500 MN1020 Thermoscientific 
KIF5A Rabbit 5% milk/TBS-Tween 1:1000 HPA004469 Sigma-Aldrich 
KIF21B Rabbit 5% milk/TBS-Tween 1:1000 HPA027274 Sigma-Aldrich 
KIF1B Rabbit 5% milk/TBS-Tween 1:500 A301-055A Bethyl Labs 
NeuN Rabbit 5% milk/TBS-Tween 1:5000 Ab177487 Abcam 
Abbreviations: AβPP: amyloid β protein precursor; BSA: Bovine serum albumin; DB: dot-blotting; KIF: kinesin superfamily protein; NeuN: neuronal nuclei; PHF: paired-
helical filament; TBS: Tris-buffered saline; WB: western blotting. 
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Table 3. Multiple regression analysis of cohort variables on KIF mRNA expression 
Significant correlations highlighted in red. Abbreviations: ENO-2: enolase-2; KIF: kinesin superfamily protein; NeuN: neuronal nuclei. 
 
 
 
 
 
 
 
 
 
Sample 
type 
n Variables Coefficient 
Standard 
error 
t p value 
95% 
Confidence 
intervals 
KIF5A to 
NeuN  
44 
Treatment group 1.12 0.39 2.85 0.01 0.32 1.92 
Age at death 0.03 0.03 0.96 0.35 -0.04 0.10 
Post-mortem delay 0.02 0.01 2.29 0.03 0.00 0.04 
Gender -0.11 0.48 -0.22 0.83 -1.08 0.87 
KIF1B to 
NeuN  
46 
Treatment group 1.22 0.45 2.71 0.01 0.31 2.13 
Age at death -0.01 0.02 -0.43 0.67 -0.06 0.04 
Post-mortem delay 0.03 0.01 3.09 0.00 0.01 0.05 
Gender 0.64 0.46 1.39 0.17 -0.29 1.58 
KIF21B to 
NeuN  
45 
 
Treatment group 0.13 0.09 1.38 0.18 -0.06 0.32 
Age at death 0.01 0.01 1.40 0.17 -0.00 0.00 
Post-mortem delay -0.00 0.00 -0.36 0.72 -0.15 0.28 
Gender 0.07 0.11 0.63 0.53 -0.90 1.42 
KIF5A to 
ENO-2 
45 
Treatment group 1.43 0.31 4.54 0.00 0.79 2.06 
Age at death -0.04 0.02 -2.00 0.05 -0.07 0.00 
Post-mortem delay -0.00 0.01 -0.21 0.84 -0.02 0.02 
Gender 0.05 0.35 0.13 0.89 -0.65 0.74 
KIF1B to 
ENO-2 
44 
Treatment group 0.95 0.33 2.86 0.01 0.28 1.63 
Age at death -0.04 0.02 -2.04 0.05 -0.08 -0.00 
Post-mortem delay -0.00 0.01 -0.25 0.80 -0.02 0.01 
Gender -0.16 0.34 -0.46 0.64 -0.85 0.53 
KIF21B to 
ENO-2 
45 
Treatment group 0.59 0.61 0.97 0.34 -0.64 1.81 
Age at death -0.03 0.04 -0.76 0.46 -0.12 0.05 
Post-mortem delay -0.03 0.02 -1.75 0.09 -0.06 0.00 
Gender -0.27 0.68 -0.40 0.69 -1.64 1.10 
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Table 4. Multiple regression analysis of cohort variables on protein expression 
Significant correlations highlighted in red. Abbreviations: : Aβ: amyloid β; AD: Alzheimer’s disease, AβPP: amyloid β protein precursor; PHF: paired-helical filament; KIF: 
kinesin superfamily protein. 
 
 
 
Sample 
type 
n Variables Coefficient 
Standard 
error 
t p value 
95% 
Confidence 
intervals 
KIF5A  64 
Treatment group -0.53 0.14 -3.87 0.00 -0.80 -0.26 
Age at death -0.01 0.01 -1.64 0.11 -0.03 0.00 
Post-mortem delay 0.00 0.00 1.15 0.25 -0.00 0.01 
Gender 0.03 0.14 0.19 0.85 -0.25 0.31 
KIF1B 80 
Treatment group 1.01 0.21 4.91 0.00 0.60 1.42 
Age at death -0.03 0.01 -2.80 0.01 -0.05 -0.01 
Post-mortem delay 0.01 0.00 1.91 0.06 -0.00 0.02 
Gender 0.11 0.21 0.53 0.60 -0.31 0.54 
KIF21B 
75 
 
Treatment group 0.53 0.15 3.62 0.00 0.24 0.81 
Age at death -0.01 0.01 -0.98 0.33 -0.03 0.01 
Post-mortem delay 0.00 0.00 0.90 0.37 -0.00 0.01 
Gender 0.02 0.16 0.12 0.91 -0.29 0.33 
AβPP 81 
Treatment group 1.40 0.95 1.46 0.15 -0.50 3.30 
Age at death -0.08 0.05 -1.42 0.16 -0.18 0.03 
Post-mortem delay 0.04 0.02 1.73 0.09 -0.01 0.09 
Gender 0.73 0.98 0.75 0.46 -1.22 2.69 
PHF-Tau 77 
Treatment group -0.16 0.02 -8.32 0.00 -0.19 -0.12 
Age at death 0.00 0.00 2.07 0.04 0.00 0.00 
Post-mortem delay -0.00 0.00 -1.42 0.16 -0.00 0.00 
Gender -0.03 0.02 -1.28 0.21 -0.07 0.01 
Insoluble 
Aβ 
68 
Treatment group 128.70 15.87 8.11 0.00 96.99 160.42 
Age at death 0.61 0.69 0.89 0.38 -0.76 1.99 
Post-mortem delay -0.04 0.50 -0.09 0.93 -1.04 0.95 
Gender -1.91 17.03 -0.11 0.91 -35.93 32.12 
  Treatment group 0.35 0.17 2.04 0.05 0.01 0.69 
Soluble Aβ 63 Age at death 0.01 0.01 0.89 0.38 -0.01 0.02 
  Post-mortem delay -0.01 0.00 -1.92 0.06 -0.02 0.00 
  Gender 0.15 0.16 0.89 0.38 -0.18 0.47 
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Table 5. Correlation analysis of kinesin superfamily protein with proteins linked to Alzheimer’s disease. 
Significant correlations highlighted in red. Aβ: amyloid-β; AD: Alzheimer’s disease, AβPP: amyloid β protein precursor; KIF: kinesin superfamily motor protein; PHF: 
paired-helical filament. 
 
 
 
 
Motor protein Cargo protein Sample n 
Correlation  
coefficient (r) 
Significance (p) 
KIF5A 
 
AβPP 
Control 33 -0.42 0.02 
AD 41 -0.53 0.00 
PHF-Tau 
Control 32 -0.34 0.09 
AD 42 -0.27 0.10 
Insoluble Aβ 
Control 24 -0.08 0.70 
AD 26 0.05 0.81 
Soluble Aβ 
Control 20 -0.15 0.52 
AD 24 -0.49 0.02 
Soluble: Insoluble Aβ 
Control 18 0.10 0.69 
AD 24 -0.35 0.09 
KIF1B 
 
AβPP 
Control 32 -0.17 0.36 
AD 40 -0.18 0.26 
PHF-Tau 
Control 31 0.09 0.63 
AD 38 0.23 0.16 
Insoluble Aβ 
Control 22 -0.28 0.21 
AD 38 0.10 0.57 
Soluble Aβ 
Control 17 0.15 0.58 
AD 34 -0.16 0.37 
Soluble: Insoluble Aβ 
Control 17 0.21 0.43 
AD 37 -0.19 0.27 
KIF21B 
 
AβPP 
Control 33 -0.30 0.09 
AD 43 -0.15 0.34 
PHF-Tau 
Control 32 -0.30 0.10 
AD 40 -0.07 0.66 
Insoluble Aβ 
Control 25 -0.15 0.49 
AD 40 -0.10 0.54 
Soluble Aβ 
Control 19 -0.09 0.73 
AD 36 -0.09 0.61 
Soluble: Insoluble Aβ 
Control 19 0.05 0.85 
AD 38 0.11 0.53 
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Table 6. Multiple regression analysis of KIF, age and tau protein expression 
Significant correlations highlighted in red. AD: Alzheimer’s disease, KIF: kinesin superfamily motor protein; PHF: paired-helical filament. 
 
  
KIF 
protein 
Sample 
type 
n Variables Coefficient 
Standard 
error 
t 
p 
value 
95% 
Confidence 
intervals 
KIF5A 
Control 32 
Age at death -0.73 0.95 -0.77 0.45 -2.67 1.22 
PHF-Tau -34.13 23.36 -1.46 0.16 -81.91 13.64 
AD 39 
Age at death -0.01 0.02 -0.78 0.44 -0.05 0.02 
PHF-Tau -0.00 0.00 -2.14 0.04 -0.00 -0.00 
KIF1B 
Control 31 
Age at death -0.81 0.56 -1.45 0.16 -1.95 0.33 
PHF-Tau 11.70 9.51 1.23 0.23 -7.78 31.18 
AD 38 
Age at death -1.61 1.73 -0.93 0.36 -5.12 1.91 
PHF-Tau 0.02 0.04 0.56 0.58 -0.06 0.11 
KIF21B 
Control 32 
Age at death 0.22 0.43 0.51 0.61 -0.66 1.10 
PHF-Tau -13.19 8.49 -1.55 0.13 -30.55 4.17 
AD 40 
Age at death -0.02 0.02 -1.27 0.21 -0.05 0.01 
PHF-Tau -0.00 0.00 -1.00 0.32 -0.00 0.00 
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Figures legends/Figures 
 
Figure 1. Upregulated gene expression of anterograde kinesin motors in Alzheimer’s disease:  quantitative 
real-time PCR performed with cDNA samples obtained from homogenised brain frontal lobe sections show a 
significant increase in KIF5A mRNA expression in AD cases (n=23) compared to control (n=22), when 
normalised to ENO-2 (A). KIF1B mRNA expression is significantly increased in AD cases (n=23) compared with 
control (n=22), when normalised to ENO-2 (B). KIF21B mRNA expression is not significantly different between 
control (n=21) and AD cases (n=23), when normalised to ENO-2 (C). Results expressed as median, IQR and 
min/max quartile. Statistical test used: two-tailed Mann-Whitney; **p<0.01, ***p<0.001. AD: Alzheimer’s 
disease, IQR: inter-quartile range, KIF: kinesin superfamily protein, ENO-2: enolase-2. 
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Figure 2. Increased anterograde kinesin motor protein expression in Alzheimer’s disease:  Protein levels 
derived from immuno dot-blot show a significant increase in anterograde kinesin motor protein KIF5A expression 
in AD cases (n=43), compared with control (n=35), when normalised to NeuN (A). KIF1B protein expression is 
significantly increased in AD cases (n=42), compared with control (n=33), when normalised to NeuN (B). KIF21B 
protein expression is significantly increased in AD cases (n=44), compared with control (n=36), when normalised 
to NeuN (C). Results expressed as median, IQR and min/max quartile. Statistical test used: two-tailed Mann-
Whitney; *p<0.05, ***p<0.001. AD: Alzheimer’s disease, IQR: inter-quartile range, KIF: kinesin superfamily 
protein, NeuN: neuronal nuclei. 
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Figure 3. Elevated hyperphosphorylated tau protein expression in AD cases. Protein levels derived from 
immuno dot-blot show a significant increase in PHF-tau expression in AD cases (n=42) compared with control 
(n=35), when normalised to NeuN (A). Univariate analysis shows no significant correlation between KIF5A and 
PHF-Tau levels in AD cases (n=42; B). Results expressed as median, IQR and min/max quartile. Statistical test 
used: two-tailed Mann-Whitney (A). Correlation represented as line of best fit +/- 95% CI (B). ***p<0.001. AD: 
Alzheimer’s disease, CI: confidence interval, IQR: inter-quartile range, KIF: kinesin superfamily motor protein, 
NeuN: neuronal nuclei, PHF: paired helical filament. 
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Figure 4. Higher kinesin motor KIF5A protein levels correlate with lower levels of amyloid precursor 
protein and soluble Aβ in AD. Protein levels derived from immuno dot-blot show a significant increase in AβPP 
expression in AD cases (n=45) compared with control (n=36), when normalised to NeuN (A). Significant inverse 
correlation between KIF5A protein levels normalised to GAPDH and AβPP protein levels, normalised to NeuN 
in AD (n=41; B).  Protein levels obtained via ELISA show no significant difference in soluble Aβ protein 
expression in AD cases (n=42) compared with control (n=22; C). Significant inverse correlation between KIF5A 
protein levels normalised to NeuN and soluble Aβ protein levels in AD (n=24; D). Results expressed as median, 
IQR and min/max quartile. Statistical test used: two-tailed Mann-Whitney (A and C). Correlations represented as 
line of best fit +/- 95% CI (B and D). *p<0.05, ** p<0.01, ***p<0.001. Aβ: amyloid-β, AD: Alzheimer’s disease, 
AβPP: amyloid β protein precursor, CI: confidence intervals, IQR: inter-quartile range, KIF: kinesin superfamily 
protein, NeuN: neuronal nuclei. 
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Supplementary Table 1. Analysis of Braak score on KIF expression using one-way ANOVA. 
Bonferroni’s 
Multiple 
Comparison 
Test 
Mean 
difference 
t 
Significant? 
p<0.05? 
Summary 
95% CI of 
difference 
KIF5A 
0 vs 1 27.01 0.14 No ns -576.0 630.1 
0 vs 2 -62.43 0.42 No ns -531.2 406.3 
0 vs 3 -43.38 0.26 No ns -565.6 478.9 
0 vs 4 52.38 0.29 No ns -524.6 630.2 
0 vs 5 -141.50 0.93 No ns -618.2 335.3 
0 vs 6 -133.60 0.87 No ns -615.6 348.4 
1 vs 2 -89.45 0.60 No ns -558.2 -379.3 
1 vs 3 -70.39 0.42 No ns -592.7 451.9 
1 vs 4 25.81 0.14 No ns -551.6 603.2 
1 vs 5 -168.50 1.11 No ns -645.2  308.3 
1 vs 6 -160.60 1.05 No ns -642.7 321.4 
2 vs 3 19.05 0.17 No ns -339.8 377.9 
2 vs 4 115.30 0.83 No ns -320.0 550.5 
2 vs 5 -79.04 0.86 No ns -367.7 209.7 
2 vs 6 -71.19 0.75 No ns -368.5 226.1 
3 vs 4 96.21 0.61 No ns -396.2 588.6 
3 vs 5 -98.09 0.83 No ns -467.4 271.2 
3 vs 6 -90.24 0.75 No ns -466.3 285.8 
4 vs 5 -194.30 1.37 No ns -638.1 249.5 
4 vs 6 -186.50 1.30 No ns -635.9 263.0 
5 vs 6 7.84 0.08 No ns -301.9 317.6 
KIF1B 
0 vs 1 
0 vs 2 
0 vs 3 
0 vs 4 
-15.06 0.09 No ns -552.7 522.6 
-8.04 0.06 No ns -433.1 417.0 
-74.14 0.50 No ns -539.8 391.5 
-46.46 0.29 No ns -544.2 451.3 
0 vs 5 -265.40 1.96 No ns -690.4 159.7 
0 vs 6 
1 vs 2 
1 vs 3 
1 vs 4 
-211.90 1.52 No ns -650.9 227.1 
7.02 0.05 No ns -418.0 432.1 
-59.08 0.40 No ns -524.7 406.6 
-31.40 0.20 No ns -529.2 466.4 
1 vs 5 
1 vs 6 
2 vs 3 
2 vs 4 
-250.30 1.85 No ns -675.4 174.7 
-196.80 1.41 No ns -635.8 242.2 
-66.10 0.63 No ns -395.3 263.2 
-38.42 0.32 No ns -411.8 334.9 
2 vs 5 
2 vs 6 
3 vs 4 
3 vs 5 
-257.30 3.01 No ns -526.2 11.5 
-203.80 2.21 No ns -494.2 86.5 
27.67 0.21 No ns -391.3 446.6 
-191.20 1.83 No ns -520.5 138.0 
3 vs 6 
4 vs 5 
4 vs 6 
5 vs 6 
-137.70 1.25 No ns -484.8 209.3 
-218.90 1.84 No ns -592.2 154.4 
-165.40 1.34 No ns -554.5 223.7 
53.50 0.58 No ns -236.9 343.9 
KIF21B 
0 vs 1 
0 vs 2 
0 vs 3 
0 vs 4 
14.89 0.17 No ns -264.8 294.5 
-18.04 0.26 No ns -236.2 200.1 
-87.39 1.13 No ns -329.6 154.8 
-1.50 0.02 No ns -260.4 257.4 
0 vs 5 -93.94 1.33 No ns -316.2 128.3 
0 vs 6 -140.0 1.95 No ns -364.9 85.0 
1 vs 2 -32.93 0.47 No ns -251.1 185.2 
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1 vs 3 -102.30 1.33 No ns -344.5 139.9 
1 vs 4 -16.39 0.20 No ns -275.3 242.5 
1 vs 5 -108.80 1.54 No ns -331.1 113.4 
1 vs 6 -154.9 2.16 No ns -379.8 70.1 
2 vs 3 -69.35 1.30 No ns -236.8 98.1 
2 vs 4 16.54 0.27 No ns -174.3 207.4 
2 vs 5 -75.90 1.74 No ns -213.0 61.2 
2 vs 6 -121.90 2.71 No ns -263.4 19.5 
3 vs 4 85.89 1.24 No ns -132.0 303.8 
3 vs 5 -6.55 0.12 No ns -179.3 166.2 
3 vs 6 -52.58 0.94 No ns -228.8 123.6 
4 vs 5 -92.44 1.48 No ns -287.9 103.1 
4 vs 6 -138.50 2.19 No ns -337.0 60.1 
5 vs 6 -46.04 0.98 No ns -193.7 101.6 
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Supplementary Table 2. Multiple regression analysis of KIF1B, age and Aβ protein expression 
Significant correlations highlighted in red. Aβ: amyloid-β; AD: Alzheimer’s disease, AβPP: amyloid β protein precursor; KIF: kinesin superfamily motor protein. 
  
KIF 
protein 
Sample 
type 
n Variables Coefficient 
Standard 
error 
t 
p 
value 
95% 
Confidence 
intervals 
KIF1B 
Control 32 
Age at death -0.60 0.49 -1.23 0.23 -1.59 0.40 
AβPP -1.54 1.66 -0.93 0.36 -4.93 1.84 
AD 40 
Age at death -3.04 1.16 -2.61 0.01 -5.40 -0.68 
AβPP -4.10 1.37 -3.00 0.01 -6.87 -1.33 
KIF1B 
Control 22 
Age at death -0.32 0.82 -0.39 0.70 -2.04 1.41 
Insoluble Aβ 91.04 65.26 1.40 0.18 -45.54 227.63 
AD 38 
Age at death -0.05 0.02 -2.89 0.01 -0.08 -0.01 
Insoluble Aβ 0.00 0.00 1.09 0.28 -0.00 0.00 
KIF1B 
Control 19 
Age at death -0.21 0.89 -0.24 0.81 -2.11 1.68 
Soluble Aβ -0.35 13.84 -0.03 0.98 -29.69 28.99 
AD 37 
Age at death -0.04 0.16 -2.53 0.02 -0.07 -0.01 
Soluble Aβ -0.31 0.16 -1.90 0.07 -0.64 0.02 
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Supplementary Figure 1. Antibody specificity. Western blots were performed using Alzheimer’s disease protein 
homogenates, derived from frontal lobe, to determine antibody specificity. Predicted molecular weight of KIF5A 
107kDa and 117kDa. Antibody used for band detection was rabbit anti-KIF5A 1:1000; Sigma-Aldrich; 
HPA004469 (A). Predicted molecular weight of KIF21B 180kDa. Antibody used for detection was rabbit anti-
KIF21B 1:1000; Sigma-Aldrich; HPA027274 (B). Predicted molecular weight of KIF1B 200kDa. Antibody used 
for detection was rabbit anti-KIF1B 1:1500; Bethyl Laboratories; A301-055A (C). Predicted molecular weight of 
APP 110kDa. Antibody used for detection was mouse anti-APP 1:2000; Zymed; 13-0200 (D). Predicted molecular 
weight of Tau 45-65kDa. Antibody used for detection was mouse anti-PHF-Tau 1:500; Thermoscientific; 
MN1020 (E). Predicted molecular weight of GAPDH 37kDa. Antibody used for detection was mouse anti-
GAPDH 1:10,000; Abcam; Ab9484 (F). Predicted molecular weight of NeuN 48kDa. Antibody used for detection 
was rabbit anti-NeuN 1:5000; Abcam; Ab177487 (G). APP: amyloid precursor protein; GAPDH: Glyceraldehyde 
3-phosphate dehydrogenase; kDa: kilodaltons; KIFs: kinesin superfamily proteins; MW; molecular weight; NeuN: 
neuronal nuclei. 
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